NCT04535882

Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD

Association Between Serum Leucine-rich Alpha-2 Glycoprotein Levels and Endoscopic Activity of Possible Ulcerative Colitis or Crohn's Disease Colitis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 125 (actual)
• Sponsor: Showa Inan General Hospital · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: —

Summary

We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.

Detailed description

Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy with histology were performed within 7 days.The disease activity of UC and CD patients was evaluated by the Mayo score and Crohn disease activity index (CDAI), respectively. The Mayo endoscopy score was evaluated. UC patients whose Mayo endoscopy score was 2 or 3 were divided into the active UC group. CD patients whose CDAI \>150 were divided into the active CD group.

Conditions

• LRG Levels

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	serum leucine-rich alpha-2 glycoprotein (LRG) levels	Patients who were diagnosed with possible UC or Crohn disease according to endoscopic, radiological, histological, and clinical criteria were enrolled. Serum samples were collected from patients, and scores for clinical and endoscopic activity of disease were obtained by reviewing the clinical records of patients. Serum sampling and colonoscopy were performed within 7 days.

Timeline

• Start date: 2020-10-01
• Primary completion: 2024-12-31
• Completion: 2024-12-31
• First posted: 2020-09-02
• Last updated: 2025-05-15

Locations

1 site across 1 country: Japan